Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Detrusor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    85 result(s) found for: Detrusor. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2006-005523-42 Sponsor Protocol Number: 905-EC-005 Start Date*: 2007-09-05
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A randomized, double blind, double dummy, placebo controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10mg once daily) against placebo and oxybutynin hydrochloride ...
    Medical condition: Neurogenic detrusor overactivity.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) NL (Completed) GB (Completed) HU (Completed) FR (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003178-22 Sponsor Protocol Number: 905-CL-074 Start Date*: 2013-04-17
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose -Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Child...
    Medical condition: Neurogenic Detrusor Overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10012547 Detrusor hyperreflexia LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) BE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000330-11 Sponsor Protocol Number: 905-CL-047 Start Date*: 2012-02-09
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 3, Open-Label, Baseline-controlled, Multicenter, Sequential Dose Titration Study to Assess the Long-Term Efficacy and Safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in...
    Medical condition: Neurogenic Detrusor Overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004857 10012547 Detrusor hyperreflexia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) NL (Completed) DK (Completed) DE (Completed) FR (Ongoing) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-003159-12 Sponsor Protocol Number: 8405011 Start Date*: 2012-09-24
    Sponsor Name:APOGEPHA Arzneimittel GmbH
    Full Title: Efficacy of propiverine hydrochloride extended release (ER) 45 mg in patients with neurogenic detrusor overactivity – an active-controlled single center crossover trial
    Medical condition: neurogenic detrusor overactivity
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004857 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002663-11 Sponsor Protocol Number: PSD506-OAB-002 Start Date*: 2006-10-17
    Sponsor Name:Plethora Solutions Limited
    Full Title: An open-label, escalating dose, proof of concept study to determine the effects of single oral doses of PSD506 on unstable urinary bladder contractions induced by volume provocation in subjects wit...
    Medical condition: Unstable urinary bladder contractions induced by volume provocation in subjects with detrusor hyper-reflexia secondary to spinal injuries above T12.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004659-30 Sponsor Protocol Number: PKM6270 Start Date*: 2015-03-17
    Sponsor Name:sanofi-aventis
    Full Title: Four-week, open-label, multicenter, randomized, parallel-group study to investigate the pharmacokinetics, safety, tolerability and the effects on leak point pressure of 2 oral doses of alfuzosin (0...
    Medical condition: Urinary Bladder Neurogenic
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-002981-39 Sponsor Protocol Number: v1.1aug05 Start Date*: 2008-09-19
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: Randomised trial of detrusor botulinum toxin injection (BOTOX®) compared to placebo in women with idiopathic detrusor overactivity
    Medical condition: Detrusor overactivity which is a disease of bladder function where unprovoked contractions of the detrusor muscle are generated during the storage phase of micturition. Symptoms include frequency, ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002640-97 Sponsor Protocol Number: A6121128 Start Date*: 2004-10-27
    Sponsor Name:Pfizer
    Full Title: Time to onset of action of tolterodine using force fill cystometry in SPINAL CORD INJURY PATIENTS WITH neurogenic detrusor overactivity.
    Medical condition: Neurogenic detrusor overactivity in patients with spinal cord injury
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: View results
    EudraCT Number: 2020-004192-41 Sponsor Protocol Number: A0221109 Start Date*: 2020-09-03
    Sponsor Name:Pfizer
    Full Title: LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR ...
    Medical condition: Urinary Bladder, Neurogenic
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023210-31 Sponsor Protocol Number: Y52-52120-155 Start Date*: 2012-02-24
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNIT...
    Medical condition: NEUROGENIC DETRUSOR OVERACTIVITY
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) LT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-002397-38 Sponsor Protocol Number: EFC5722 Start Date*: 2007-09-03
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: 12-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy, pharmacodynamic and safety of two doses of alfuzosin (0.1 mg/kg/day; 0.2 mg/kg/...
    Medical condition: Children with voiding dysfunction of neuropathic etiology
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047685 Voiding difficulty LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) DE (Completed) ES (Completed) PL (Completed) EE (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-005868-93 Sponsor Protocol Number: AV608-106 Start Date*: 2006-05-15
    Sponsor Name:AVERA PHARMACEUTICALS INC.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects with Idiopathic Detrusor Overactivity
    Medical condition: Idiopathic Detrusor Overactivity (Overactive Bladder)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003068-47 Sponsor Protocol Number: UROBOTOX 1 Start Date*: 2005-09-22
    Sponsor Name:Region Skåne, Universitetssjukhuset i Lund, Urologiska kliniken
    Full Title: Behandling med botulinumtoxin vid neurogen blåsfunktionsstörning
    Medical condition: The trial addresses patients with severe symptoms of neurogenic detrusor overactivity (urgency and/or urge incontinence). Eligible are those patients who have failed conservative treatment such as ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004011-30 Sponsor Protocol Number: 987654321 Start Date*: 2005-12-02
    Sponsor Name:Gwent Healthcare NHS Trust
    Full Title: A prospective open study evaluating the use of botulinum toxin in patients with overactive bladder as an alternative to other conservative treatments.
    Medical condition: Overactive bladder syndrome is characterized by a combination of urinary frequency, urgency and urge incontinence.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000250-28 Sponsor Protocol Number: 905-CL-079 Start Date*: 2011-11-15
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with...
    Medical condition: Neurogenic Detrusor Overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10012547 Detrusor hyperreflexia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-004650-93 Sponsor Protocol Number: botuline5 Start Date*: 2007-10-10
    Sponsor Name:University Medical Center Groningen
    Full Title: The effect of Botulinum toxin A injections for overactive bladder on detrusor contractility
    Medical condition: Neurogenic or idiopathic overactive bladder, not adequately responding to anticholinergic therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004716-75 Sponsor Protocol Number: SO5 UROL 468 Start Date*: 2006-01-18
    Sponsor Name:Swansea NHS Trust
    Full Title: A double blind, randomised, placebo controlled crossover study of intra-trigonal injections of Botulinum toxin type B for treating patients with idiopathic detrusor overactivity refractory to other...
    Medical condition: Idiopathic detrusor overactivity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013334-24 Sponsor Protocol Number: KN0203Y-001 Start Date*: 2010-01-08
    Sponsor Name:KeyNeurotek Pharma GmbH
    Full Title: Double-blind placebo-controlled proof of concept study with the µ-receptor agonist KN203 in patients with overactive bladder syndrome Double-blind, randomized, parallel groups prospective phase II-...
    Medical condition: Women with urgency-frequency syndrome with urinary incontinence due to detrusor instability diagnosed by cystometry. oder Patients with overactive bladder with or without urinary urge incontinenc...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10059617 Overactive bladder LLT
    12.0 10012548 Detrusor instability LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022475-55 Sponsor Protocol Number: A0221047 Start Date*: 2012-07-20
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A 24-WEEK RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 17 YEARS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDI...
    Medical condition: Neurogenic Detrusor Overactivity (NDO).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10029279 Neurogenic bladder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) EE (Completed) FI (Completed) SK (Completed) GB (Completed) ES (Completed) GR (Completed) FR (Completed) NL (Completed) BE (Completed) RO (Ongoing) DK (Prematurely Ended) DE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000340-15 Sponsor Protocol Number: 178-CL-202 Start Date*: 2014-07-11
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A multicentre, open-label, single ascending dose Phase 1 study to evaluate the pharmacokinetics, safety and tolerability of mirabegron OCAS tablets in pediatric subjects from 5 to less than 18 year...
    Medical condition: -neurogenic detrusor overactivity (NDO) -overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10012547 Detrusor hyperreflexia LLT
    16.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NO (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 12:11:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA